Biotech Values

[mcbio]

Good catch. I just assumed this was the AZN trial. So, we will see the effect of docetaxel with and without selumetinib in wild-type BRAF melanoma as opposed to dacarbazine with and without selumetinib in BRAF mutant melanoma.

In doing a bit more digging, I'm skeptical that this Oxford study that was to be reported on today (haven't seen data yet) will be positive because it appears to be in BRAF wild-type melanoma. Selumetinib has been much more active in BRAF mutant (http://www.ncbi.nlm.nih.gov/pubmed/22972589 ), which is what AZN P2 trial in BRAF melanoma is and for which the results are long overdue.